[Federal Register Volume 83, Number 55 (Wednesday, March 21, 2018)]
[Notices]
[Page 12408]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-05725]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Importer of Controlled Substances Application: Noramco, Inc.

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration on or before April 20, 2018. Such 
persons may also file a written request for a hearing on the 
application on or before April 20, 2018.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DRW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
requests for hearing should also be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, 
Springfield, Virginia 22152. Comments and requests for hearings on 
applications to import narcotic raw material are not appropriate. 72 FR 
3417 (January 25, 2007).

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, dispensers, importers, and exporters of 
controlled substances (other than final orders in connection with 
suspension, denial, or revocation of registration) has been redelegated 
to the Assistant Administrator of the DEA Diversion Control Division 
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, 
appendix to subpart R. In accordance with 21 CFR 1301.34(a), this is 
notice that on July 6, 2017, Noramco, Inc., 500 Swedes Landing Road, 
Wilmington, Delaware 19801-4417 applied to be registered as an importer 
of the following basic controlled substances:

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
Marihuana..............................     7360  I
Tetrahydrocannabinols..................     7370  I
Nabilone...............................     7379  II
Phenylacetone..........................     8501  II
Opium, raw.............................     9600  II
Poppy Straw Concentrate................     9670  II
Tapentadol.............................     9780  II
------------------------------------------------------------------------

    The company plans to import phenylacetone (8501), opium, raw 
(9600), and poppy straw concentrate (9670) to bulk manufacture other 
controlled substances for distribution to its customers. The company 
plans to import an intermediate form of tapentadol (9780) to bulk 
manufacture tapentadol (9780) for distribution to its customers.
    In reference to drug codes 7360 and 7370, the company plans to 
import a synthetic cannabidiol and a synthetic tetrahydrocannabinol. No 
other activity for these drug codes is authorized for this 
registration. Placement of these drug codes onto the company's 
registration does not translate into automatic approval of subsequent 
permit applications to import controlled substances. Approval of permit 
applications will occur only when the registrant's business activity is 
consistent with what is authorized under 21 U.S.C 952(a)(2). 
Authorization will not extend to the import of FDA approved or non-
approved finished dosage forms for commercial sale.

    Dated: March 15, 2018.
Susan A. Gibson,
Deputy Assistant Administrator.
[FR Doc. 2018-05725 Filed 3-20-18; 8:45 am]
 BILLING CODE 4410-09-P